Author: McAulay, Kathrine; Bryan, Andrew; Greninger, Alexander L.; Grill, Francisca; Lake, Douglas; Kaleta, Erin J.; Grys, Thomas E.
Title: Retrospective clinical evaluation of four lateral flow assays for the detection of SARS-CoV-2 IgG Cord-id: 2oer99uj Document date: 2020_8_2
ID: 2oer99uj
Snippet: In a CLIA laboratory setting, we evaluated SARS-CoV-2 IgG detection with four lateral flow immunoassays [LFIAs; two iterations from BTNX Inc. (n = 457), and one each from ACON Laboratories (n = 200); and SD BIOSENSOR (n = 155)]. In a cohort of primarily hospitalized, RT-PCR confirmed COVID-19 cases, sensitivity at ≥14 days from symptom onset was: BTNX kit 1, 95%; BTNX kit 2, 91%; ACON, 95%; and SD, 92%. All assays showed good concordance with the Abbott SARS-CoV-2 IgG assay at ≥14 days from
Document: In a CLIA laboratory setting, we evaluated SARS-CoV-2 IgG detection with four lateral flow immunoassays [LFIAs; two iterations from BTNX Inc. (n = 457), and one each from ACON Laboratories (n = 200); and SD BIOSENSOR (n = 155)]. In a cohort of primarily hospitalized, RT-PCR confirmed COVID-19 cases, sensitivity at ≥14 days from symptom onset was: BTNX kit 1, 95%; BTNX kit 2, 91%; ACON, 95%; and SD, 92%. All assays showed good concordance with the Abbott SARS-CoV-2 IgG assay at ≥14 days from symptom onset: BTNX kit 1, 99%; BTNX kit 2, 94%; ACON, 99%; and SD, 100%. Specificity, measured using specimens collected prior to SARS-CoV-2 circulation in the US and “cross-reactivity challenge†specimens, was 98% for BTNX kit 1 and ACON and 100% for BTNX kit 2 and SD. These results suggest that LFIAs may provide adequate results for rapid detection of SARS-CoV-2.
Search related documents:
Co phrase search for related documents- abbott sars and low prevalence setting: 1
- abbott test and low prevalence setting: 1
- additional study and adequate level: 1
Co phrase search for related documents, hyperlinks ordered by date